ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P TSX Capped Composite...
32.63
(
1.02%
)
US Tech 100
15,626.00
(
0.47%
)
S&P 500
4,594.63
(
0.59%
)
US Dollar vs CAD
1.34975
(
0.0%
)
Bitcoin
38,767.79
(
0.16%
)
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) News

BHVN Biohaven Ltd

33.70
0.38 (1.14%)
Dec 01 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Biohaven Ltd BHVN NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.38 1.14% 33.70 15:40:09
Open Price Low Price High Price Close Price Previous Close
33.20 32.46 33.85 33.66 33.32
more quote information »

Recent News

Date Time Source Heading
12/01/202315:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
11/14/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/14/202315:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
10/16/202306:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
10/05/202315:05EDGAR2Form 8-K - Current report
10/05/202315:05PRNUSBiohaven Announces Closing of Public Offering and Full..
10/04/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/02/202322:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
10/02/202320:41EDGAR2Form 8-K - Current report
10/02/202316:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/02/202316:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/02/202315:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
10/02/202315:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
9/27/202305:58EDGAR2Form 8-K - Current report
9/14/202306:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
9/05/202306:00PRNUSBiohaven Announces Positive Data from its Exploratory..
7/31/202316:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
7/31/202315:29EDGAR2Form 8-K - Current report
7/31/202308:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
7/31/202305:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
7/28/202315:35EDGAR2Form 8-K - Current report
7/27/202307:42DJNBiohaven Told That FDA Won't Review NDA Application for..
7/27/202306:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..
5/31/202306:00PRNUSBiohaven Provides Overview of Clinical Progress, Regulatory..
5/25/202316:00PRNUSBiohaven to Present R&D Day at Yale School of Management
5/12/202315:30PRNUSBiohaven Reports First Quarter 2023 Financial Results and..
4/17/202306:00PRNUSBiohaven Expands Executive Leadership Team with Appointment..
3/23/202315:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2022 Financial..
3/22/202306:30PRNUSBiohaven Acquires Exclusive License for Oral,..
3/14/202306:30PRNUSBiohaven Announces Presentation at the American Society for..
2/21/202307:16DJNBiohaven Gets FDA Fast-Track Tag for Taldefgrobep in Spinal..
2/21/202306:30PRNUSBiohaven's Taldefgrobep Alfa Receives FDA Fast Track..
1/06/202306:30PRNUSBiohaven to Present at the 41st Annual J.P. Morgan..

Your Recent History

NYSE
BHVN
Biohaven
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com